Who is the sponsor?
National Institute of Health (NIH) and National Eye Institute (NEI).
Who are the patients?
Individuals with macular edema (swelling of the central part of the retina) associated with Age-Related Macular Degeneration. The participating doctor will evaluate the patient to determine his/her eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.
What is this study investigating?
This study compares the efficacy of FDA-approved ranibizumab (Lucentis) to off-label bevacizumab (Avastin), in individuals with wet macular degeneration.
How is the treatment administered?
Both drugs are administered through intravitreal injection.